Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (CGC -5.95%) and Novavax (NVAX 0.92%). 1. Canopy GrowthCanopy Growth emerged as a leader in the cannabis industry toward the end o ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous administration of TNX-801 yielded equivalent protection to the traditional percutaneous administration CHATHAM, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of develo ...

Core Insights - Tonix Pharmaceuticals announced that its vaccine candidate TNX-801 provides durable protection against monkeypox after a single dose [1][3] - The vaccine is well tolerated in immunocompromised animals, showing no evidence of spreading to blood or tissues even at high doses [2][3] - TNX-801 is designed to generate both humoral and cellular immunity and serves as a platform for delivering multiple protective antigens against various viral pathogens [3][4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing therapies for pain management and vaccines for public health challenges [6] - The company has a diverse development portfolio, including TNX-102 SL for fibromyalgia, which has a PDUFA goal date of August 15, 2025 [6] - Tonix's infectious disease portfolio includes TNX-801 for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million with the U.S. Department of Defense [6]

William Blair 45th Annual Growth Stock Conference Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases June 2025 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market share as of and for the quarter ended M ...

Ghana plans to ask India for support to develop a vaccine hub when Prime Minister Narendra Modi visits the West African nation this week https://t.co/c392lZq4ty ...

Core Points - Bavarian Nordic A/S has initiated two clinical trials for the MVA-BN mpox/smallpox vaccine targeting vulnerable populations, specifically infants under 2 years and pregnant or breastfeeding women [1][2] - The first study involves 344 infants aged 4-24 months, while the second study aims to enroll 359 women [1][2] - Both studies are conducted in the Democratic Republic of Congo, the epicenter of the ongoing mpox outbreak [1] - Bavarian Nordic is also sponsoring a trial for children aged 2-11 years, with topline results expected in Q3 2025 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [4] - The vaccine was originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure supply for the entire population, including immunocompromised individuals [4]

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age. This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for persons 12 years of age and ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strategy and ...

Core Viewpoint - Novavax, Inc. announced positive results from the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial, indicating that both vaccine candidates induced immune responses comparable to licensed vaccines Nuvaxovid® and Fluzone HD [1][2][3] Group 1: Trial Results - The Phase 3 trial involved approximately 2,000 adults aged 65 and older, focusing on the safety and immunogenicity of the CIC and tNIV compared to Nuvaxovid and Fluzone HD [3] - Both vaccine candidates demonstrated robust immune responses, with neutralizing antibody responses increasing by 2.4 to 5.7 times over baseline [2][6] - The trial results showed that nearly all solicited adverse events (>98%) were mild or moderate, indicating good tolerability [2][6] Group 2: Future Development - The data from this trial will inform future discussions with potential partners regarding the registrational Phase 3 program for the CIC and tNIV vaccines [2][3] - Novavax continues to seek partnerships to advance the development of these vaccine programs [6]

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, although more robust with the full doseSix-month data confirm full dose selection for pivotal Phase 3 trial Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 cli ...